- (2025): Lin JX+, Transl Lung Cancer Res 14(4), 1482-1495 [REVIEW]
- (2024): Wang Y+, Ther Adv Med Oncol May (e-Collection) 35%
- (2022): Cortot A+, Clin Lung Cancer Feb, Online ahead of print50%–63% [REVIEW]
Adverse reactions attributed to entire drug class 'MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor'
Please login to view adverse reactions.
- (2024): Wang Y+, Ther Adv Med Oncol May (e-Collection) 22%
- (2022): Cortot A+, Clin Lung Cancer Feb, Online ahead of print26%–46% [REVIEW]
- (2024): Wang Y+, Ther Adv Med Oncol May (e-Collection) 10%
